|
시장보고서
상품코드
2007981
부프레노르핀 시장 : 브랜드별, 유형별, 투여 경로별, 제형별, 적응증별, 처방 유형별, 연령층별, 유통 채널별, 지역별Buprenorphine Market, By Brand, By Type, By Route of Administration, By Dosage Form, By Indication, By Formulation Type, By Age Group, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
부프레노르핀 시장은 2026년에 27억 8,060만 달러로 추정되고 있으며, 2033년까지 43억 1,690만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 9.1%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 27억 8,060만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년의 예측 기간 CAGR : | 9.10% | 2033년 시장 규모 예측 : | 43억 1,690만 달러 |
부프레노르핀은 오피오이드 사용 장애 치료제로는 처음으로 진료소에서 처방 또는 조제할 수 있게 되어 치료 접근성을 크게 확대했습니다. 부프레노르핀은 다른 치료제와 마찬가지로 환자에게 전인적 접근을 제공하기 위해 상담 및 기타 서비스를 포함한 포괄적인 치료 계획의 일부로 처방되어야 합니다. 부프레노르핀은 오피오이드 사용 장애가 있거나 오피오이드 치료 센터에서의 치료가 불편하거나 부적절한 사람들에게 많은 이점을 제공합니다.
미국 식품의약국(FDA)이 오피오이드 사용 장애 치료제로 승인한 부프레노르핀 제제는 다음과 같습니다.
- 부프레노르핀/날록손 성분의 제네릭 설하정.
- 부프레노르핀 설하정(서브텍스).
- 부프레노르핀/날록손 설하 필름(서브옥손).
- 부프레노르핀/날록손 설하정(주브솔브).
- 부프레노르핀/날록손 구강내 필름(부나베일).
- 부프레노르핀 매립제(프로브핀).
- 부프레노르핀 서방형 주사제(Sublocade).
시장 역학
부프레노르핀의 피하 투여에 대한 규제 당국의 승인이 증가함에 따라 예측 기간 중 글로벌 부프레노르핀 시장은 확대될 것으로 예상됩니다. 예를 들어 2018년 3월, 제약회사 인디비오(Indivio PLC)는 피하주사제(CIII)인 SUBLOCADE(부프레노르핀 서방형) 주사제가 미국에서 출시되었다고 발표했습니다. 미국 식품의약국(FDA)은 점막투과성 부프레노르핀 함유 제제로 치료를 시작하고 최소 7일간 용량 조절을 거친 성인 환자에서 중등도에서 중증의 오피오이드 사용 장애(OUD) 치료에 서브클로케이드를 사용하도록 승인했습니다. 이 약은 의료 전문가에 의해만 투여되어야 하며, 상담 및 심리사회적 지원을 포함한 종합적인 치료 계획의 일부로 사용되어야 합니다.
본 조사의 주요 특징.
- 이 보고서는 2024년을 기준연도로 하여 예측 기간(2025-2032년) 시장 규모와 예측 기간(2025-2032년)의 CAGR을 제시하는 글로벌 부프레노르핀 시장에 대한 상세한 분석을 제공합니다.
- 이 보고서는 각 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요 인사이트도 제공합니다.
- 이 보고서는 다음과 같은 매개 변수를 기반으로 글로벌 부프레노르핀 시장의 주요 기업 개요을 작성했습니다. 구체적으로 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적 및 전략 등입니다.
- 이 보고서를 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 등급 향상, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 이 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 글로벌 부프레노르핀 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 부프레노르핀 시장 : 브랜드별, 2021-2033년
제5장 세계의 부프레노르핀 시장 : 유형별, 2021-2033년
제6장 세계의 부프레노르핀 시장 : 투여 경로별, 2021-2033년
제7장 세계의 부프레노르핀 시장 : 제형별, 2021-2033년
제8장 세계의 부프레노르핀 시장 : 적응증별, 2021-2033년
제9장 세계의 부프레노르핀 시장 : 처방 유형별, 2021-2033년
제10장 세계의 부프레노르핀 시장 : 연령층별, 2021-2033년
제11장 세계의 부프레노르핀 시장 : 유통 채널별, 2021-2033년
제12장 세계의 부프레노르핀 시장 : 지역별, 2021-2033년
제13장 경쟁 구도
제14장 애널리스트의 추천
제15장 참고 문헌 및 조사 방법
KSA 26.04.29Buprenorphine Market is estimated to be valued at USD 2,780.6 Mn in 2026 and is expected to reach USD 4,316.9 Mn by 2033, growing at a compound annual growth rate (CAGR) of 9.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2,780.6 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.10% | 2033 Value Projection: | USD 4,316.9 Mn |
Buprenorphine is the first medication to treat opioid use disorder that may be prescribed or distributed in doctor's offices, vastly expanding access to care. Buprenorphine should be prescribed as a component of a thorough treatment plan that includes counseling and other services to give patients a whole-person approach, as is the case with all drugs used in therapy. Buprenorphine provides a number of benefits for those with opioid use disorder and for those for whom therapy at an opioid treatment center is uncomfortable or inappropriate.
The following buprenorphine products are approved for the treatment of opioid use disorder by the U.S. FDA:
- Generic buprenorphine/naloxone sublingual tablets
- Buprenorphine sublingual tablets (Subutex)
- Buprenorphine/naloxone sublingual films (Suboxone)
- Buprenorphine/naloxone sublingual tablets (Zubsolv)
- Buprenorphine/naloxone buccal film (Bunavail)
- Buprenorphine implants (Probuphine)
- Buprenorphine extended-release injection (Sublocade)
Market Dynamics
Increasing approval of buprenorphine by regulatory authorities for subcutaneous use is expected to increase the global buprenorphine market over the forecast period. For instance, in March, 2018, Indivior PLC, a pharmaceutical company, announced that SUBLOCADE (buprenorphine extended-release) injection, for subcutaneous use (CIII), is available in the U.S. The U.S. Food and Drug Administration (FDA) has granted approval for the use of SUBLOCADE for the treatment of moderate to severe opioid use disorder (OUD) in adult patients who have started therapy with a transmucosal buprenorphine-containing medication and have undergone dose titration for at least seven days. It should only be given by medical professionals, and it should be part of a comprehensive treatment plan that also includes counseling and psychosocial support.
Key features of the study
- This report provides in-depth analysis of the global buprenorphine market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global buprenorphine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study are Mallinckrodt, Noramco, Unichem Laboratories Ltd., Sanofi, Johnson Matthey, Arevipharma Gmbh, Resonance Laboratories Pvt. Ltd., Sun Pharmaceutical Industries Limited, Rusan Pharma Ltd. Micro Orgo Chem, Faran Shimi Pharmaceutical, Indivior PLC, Titan Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC.
- Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global buprenorphine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global buprenorphine market
Market Segmentation
- Brand Insights (Revenue, USD Mn, 2021 - 2033)
- Sublocade (buprenorphine extendedrelease)
- Suboxone (buprenorphine and naloxone)
- Brixadi (buprenorphine extendedrelease)
- Zubsolv (buprenorphine and naloxone)
- Others (Belbuca, Butrans and among others)
- Type Insights (Revenue, USD Mn, 2021 - 2033)
- Branded
- Generics
- Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
- Injectable
- Intravenous
- Intramuscular
- Subcutaneous
- Sublingual
- Buccal
- Transdermal
- Others
- Dosage Form Insights (Revenue, USD Mn, 2021 - 2033)
- Injectable Solutions
- Patches
- Films
- Others (Tablets, etc.)
- Indication Insights (Revenue, USD Mn, 2021 - 2033)
- Opioid Use Disorder (OUD)
- Pain Management
- Acute Pain
- Chronic Pain
- Formulation Type Insights (Revenue, USD Mn, 2021 - 2033)
- Single Drug Formulation
- Fixed Dose Combination
- Age Group Insights (Revenue, USD Mn, 2021 - 2033)
- Adults
- Pediatric
- Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Indivior
- Braeburn
- Camurus
- Collegium Pharmaceutical
- Teva Pharmaceuticals
- Hikma Pharmaceuticals USA
- Alvogen
- Camber Pharmaceuticals
- Apotex
- Dr Reddy's Laboratories
- Orexo
- Rusan Pharma
- Arevipharma
- Noramco
- Neuraxpharm
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Buprenorphine Market, By Brand
- Global Buprenorphine Market, By Type
- Global Buprenorphine Market, By Route of Administration
- Global Buprenorphine Market, By Dosage Form
- Global Buprenorphine Market, By Indication
- Global Buprenorphine Market, By Formulation Type
- Global Buprenorphine Market, By Age Group
- Global Buprenorphine Market, By Distribution Channel
- Global Buprenorphine Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trends
4. Global Buprenorphine Market, By Brand, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Sublocade (buprenorphine extendedrelease)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Suboxone (buprenorphine and naloxone)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Brixadi (buprenorphine extendedrelease)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Zubsolv (buprenorphine and naloxone)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others (Belbuca, Butrans and among Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Buprenorphine Market, By Type, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Generics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Buprenorphine Market, By Route of Administration, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Intravenous
- Intramuscular
- Subcutaneous
- Sublingual
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Buccal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Transdermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. Global Buprenorphine Market, By Dosage Form, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Injectable Solutions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Patches
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Films
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others (Tablets, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
8. Global Buprenorphine Market, By Indication, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Opioid Use Disorder (OUD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Pain Management
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Acute Pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Chronic Pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
9. Global Buprenorphine Market, By Formulation Type, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Single Drug Formulation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Fixed Dose Combination
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
10. Global Buprenorphine Market, By Age Group, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
11. Global Buprenorphine Market, By Distribution Channel, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
12. Global Buprenorphine Market, By Region, 2021 - 2033, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2026,2029 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
13. Competitive Landscape
- Indivior
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Braeburn
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Camurus
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Collegium Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hikma Pharmaceuticals USA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alvogen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Camber Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Apotex
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Dr Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Orexo
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Rusan Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Arevipharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Noramco
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Neuraxpharm
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
14. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
15. References and Research Methodology
- References
- Research Methodology
- About us
샘플 요청 목록